S&P Global set a €110.00 ($127.91) price objective on Merck KGaA (FRA:MRK) in a report issued on Thursday. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other research firms also recently issued reports on MRK. Kepler Capital Markets set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Monday, November 6th. Independent Research GmbH set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Thursday. Warburg Research set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday. Berenberg Bank set a €116.00 ($134.88) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday. Finally, Commerzbank Ag set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Thursday. Thirteen analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of €108.61 ($126.29).

Shares of Merck KGaA (MRK) opened at €89.79 ($104.41) on Thursday. Merck KGaA has a 52-week low of €89.00 ($103.49) and a 52-week high of €115.00 ($133.72).

ILLEGAL ACTIVITY WARNING: “S&P Global Analysts Give Merck KGaA (MRK) a €110.00 Price Target” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/12/s110-00-price-target.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Stock Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related stocks with our FREE daily email newsletter.